Ridinilazole: a novel antimicrobial for Clostridium difficile infection

Clostridium difficile (C. difficile) infection remains a global healthcare threat worldwide and the limited options available for its treatment are of particular concern. Ridinilazole is one potential future agent, as it demonstrates rapid bactericidal activity against C. difficile. Current studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jonathan C., Crotty, Matthew P., Pardo, Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394264/
https://www.ncbi.nlm.nih.gov/pubmed/30837785
http://dx.doi.org/10.20524/aog.2018.0336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394264/
https://www.ncbi.nlm.nih.gov/pubmed/30837785
http://dx.doi.org/10.20524/aog.2018.0336

Ejemplares similares